EMA launches rolling review of GSK/Vir Biotech's mAb for early COVID-19

Retrieved on: 2021-05-10 11:37:30

Tags for this article:

Click the tags to see associated articles and topics

EMA launches rolling review of GSK/Vir Biotech's mAb for early COVID-19. View article details on hiswai:

Excerpt

... and Vir Biotechnology's SARS-CoV-2 monoclonal antibody (mAb) VIR-7831 for the early treatment of COVID-19, the companies have announced.

Article found on: www.pmlive.com